New data presented at the XXVII Congress of the European Academy of Allergology and Clinical Immunology (EAACI) in Barcelona, Spain, demonstrate AERIUS® (desloratadine) significantly reduces allergy symptoms, including nasal congestion, sneezing, rhinorrhea, nasal pruritus and ocular pruritus, in patients with intermittent allergic rhinitis (IAR) who experience symptoms lasting less than four days per week or less than four weeks per year. The results are part of the AERIUS Control: Clinical and Evaluative Profile of Treatment (ACCEPT) trials, which were conducted in collaboration with the Global Allergy and Asthma European Network (GA2LEN) and evaluated the safety and efficacy of AERIUS for the treatment of allergic rhinitis (AR), as defined by the updated Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines.
Generic amoxil pills no prescription According to the study in patients with IAR, those receiving AERIUS 5 mg for a 15-day treatment period experienced significant reduction in total symptom severity score from baseline versus placebo (-3.01 vs. -2.13; Pgeneric ultram online buy | Buy generic viagra | Buy generic fosamax